Related Experiment Video
Updated: Apr 17, 2026
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival
Li-ping Zhuang1, Zhi-qiang Meng1
1Department of Integrative Medicine, Fudan University Shanghai Cancer Center, 270 Dongan Road, Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Background:
In our previous study, we conducted a systematic screening of miRNA to identify potential serum biomarkers for predicting venous metastasis and survival in patients with hepatocellular carcinoma (HCC). miR-224 was one of the differentially expressed miRNAs. This study aimed to confirm whether serum miR-224 level is associated with the presence of venous metastasis and survival.
Methods:
TaqMan miRNA probe was used to perform qRT-PCR assays to evaluate the expression of serum miR-224 in a cohort of 182 HCC patients.
Results:
Patients with high miR-224 serum level showed poor survival compared to that with low miR-224 serum level (HR 1.985; 95% CI, 1.08, 3.65, P=0.027). The serum miR-224 levels were significantly higher in the BCLC stage C patients compared with the stage B patients (P=0.005). In further analysis, significant difference of serum miR-224 expression level was observed when patients grouped by the status of PVTT but not the status of extra-liver metastasis (P=0.013 and P=0.091). Serum levels of miR-224 showed significant relation with parameters of liver damage and serum AFP.
Conclusion:
Serum miR-224 might be BCLC stage dependent. It can reflect the status of tumor and liver damage. It was an independent predictor for the survival of HCC patients.
